Bernt van den Blink
Company: Promedior - A Member of the Roche Group
Job title: Senior Medical Director
Bernt joined Promedior in 2016 and served as the company’s global clinical lead for the development of PRM-151 in Idiopathic Pulmonary Fibrosis (IPF) and Myelofibrosis. Promedior was acquired by Roche in 2020. Prior to joining Promedior, Bernt was a faculty member in the Department of Pulmonary Medicine at the Erasmus University Medical Center (Rotterdam, The Netherlands). Board-certified in Pulmonology, Bernt has expertise in rare lung diseases, including interstitial lung diseases and lung transplantation. At ErasmusMC, he led the Inflammation and Remodeling research group focusing on translational work in interstitial lung diseases, including IPF. In addition to conducting preclinical research, he was an active clinical trial investigator.
Bernt obtained both his MD and PhD (Immunology) degrees from the University of Amsterdam, where he was also a Fellow in Internal Medicine and Pulmonology. He is the author of more than 40 peer-reviewed articles and an active member in several international lung societies.